Rheumatology   

The patient has no known history of autoimmune disease.

(e.g. beta 2 glycoprotein IgM > 20 but <40)

How would the approach differ if the patient had a significant bleeding phenotype vs only minor bruising and mucosal bleeding?

This type of etoposide sparing therapy has been previously described in a case series at https://pubmed.ncbi.nlm.nih.gov/32725881/

Would the answer differ if the index event was arterial vs venous? 

If so, how long after diagnosis do you do so? 

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?

Do you routinely check IgA anticardiolipin and beta-2 glycoprotein antibody IgA in your practice? And how would a positive result change your manageme...

e.g. DITP from eptifibatide after a cardiac intervention

i.e. obstretric APS without thrombosis or SLE

Would chemotherapy be preferred over RT? 

What if the patient is triple-positive or has continued seropositivity on repeat lab testing? What is the appropriate interval of monitoring and does ...

While low-dose aspirin for primary thrombosis prevention in aPL without APS is not typically recommended outside cardiovascular prevention guidelines ...

There are multiple difficulties that could be seen: steroids can precipitate a sickle cell crisis, vasculitis and sickle cell can produce similar clin...

Do you follow the 2019 EULAR Guidelines that SLE patients with asymptomatic, positive aPL should be on low-dose ASA?

What if this was "triple-negative" antiphospholipid syndrome?